THOR Therapeutics Inc. has announced preclinical results for their new drug candidate, THOR-221 ASO, at the 19th Annual Meeting of the Oligonucleotide Therapeutics Society during the 2023 Oligo Society conference. THOR-221 ASO is a first-in-class innovative drug being jointly researched by KAIST and THOR Therapeutics. The results presented aim to address the unmet medical needs of the cancer cachexia market, for which there is currently no effective treatment.